NRx Pharmaceuticals (Nasdaq: NRXP) has confirmed its intention to submit a New Drug Application (NDA) to the US FDA for NRX-100 (preservative-free intravenous ketamine) by June 2026, targeting a broad indication for the treatment of depression in patients with severe symptoms who may have suicidal ideation. The announcement follows a Type C guidance meeting held at FDA headquarters, attended by leadership from the Division of Psychiatry Products, the Office of Neuroscience, and the Center for Drug Evaluation and Research, the company said. NRX-100 has previously received Fast Track Designation for suicidal ideation in depression, including bipolar depression.
The filing seeks approval based on a combination of existing adequate and well-controlled clinical trial data, which the FDA agreed constitutes substantial evidence of efficacy, together with real-world evidence from Osmind, Inc. as confirmatory evidence. According to NRx Pharmaceuticals, the agency did not request additional clinical trials or nonclinical data, nor did it require bridging studies to support the preservative-free formulation. The proposed indication represents a broadening from the company’s original plan, which focused solely on patients with suicidal ideation, to now encompass severe depression more generally in patients who may also experience suicidality. The company has also noted that it anticipates at least three years of room-temperature shelf stability for the formulation.
The clinical evidence package discussed with the FDA includes trials in which ketamine demonstrated superiority to both placebo and active placebo, as well as non-inferiority to electroconvulsive therapy (ECT). The trials also showed a statistically significant reduction in suicidal ideation. NRx Pharmaceuticals highlighted that ECT, currently the only approved treatment for suicidal ideation, carries a reported 30% incidence of memory loss, whereas ketamine did not demonstrate this effect in the referenced studies. Preliminary analysis of the real-world evidence dataset further confirmed the effectiveness of intravenous ketamine in reducing both depression and suicidal ideation. Specific trial names, NCT identifiers, and detailed protocol information were not disclosed in the company’s announcement, which limits independent verification of the cited results.
The planned NDA enters a competitive landscape shaped by several recent approvals targeting depression through non-traditional mechanisms. Johnson & Johnson’s SPRAVATO (esketamine) — the S-enantiomer of ketamine, delivered as a nasal spray — received approval as a monotherapy for treatment-resistant depression in January 2025, though its label states that effectiveness in preventing suicide has not been demonstrated. Axsome Therapeutics’ Auvelity (dextromethorphan/bupropion), the first oral NMDA receptor antagonist approved for major depressive disorder, reached the market in 2022. Pipeline candidates including REL-1017 (esmethadone) from Relmada Therapeutics and COMP360 (psilocybin) from COMPASS Pathways are in Phase III development for depression. No currently approved pharmacotherapy carries a primary indication for reducing suicidal ideation — a gap NRX-100 would address if approved. The FDA’s willingness to accept real-world evidence as confirmatory data for a psychiatric NDA is itself notable, reflecting evolving regulatory standards. According to the Centers for Disease Control and Prevention, more than 16 million Americans experience depression annually and 3.6 million contemplate suicide, underscoring the scale of unmet need in this population. NRx Pharmaceuticals also has a separate Abbreviated New Drug Application pending for preservative-free ketamine under its existing anesthesia label, with an FDA decision expected in summer 2026.